Journal: bioRxiv

Article Title: ATR inhibitors synergize with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids

doi: 10.1101/2025.08.29.673024

Figure Lengend Snippet: ( A , B ) BTOR58 organoids were treated for 2h with 0,5 μM gemcitabine (GEM) ( A ) or 0,5 μM epirubicin (EPI) ( B ) alone or in combination with 0,4 μM berzosertib follow-up treatment for 72h. Weekly images were taken for 6 weeks after treatment and representative images at t=1, 3, and 6 weeks are shown. Cell viability assays at t=6 weeks are shown in ( C , D ). ( E , F ) UBTOR8 organoids were treated for 2h with 4 MMC, alone or in combination with 3,2 μM ceralasertib ( E ) or 25 nM tuvusertib ( F ) follow-up treatment for 72h. Representative images at t=1, 3, and 6 weeks after treatment are presented. Cell viability assays at t=6 weeks are shown in ( G , H ). Bar graphs represent mean with SD (n=3).

Article Snippet: Next, PDOs were washed three times with PBS, before BM2+ culture medium was added, and 20h later berzosertib, ceralasertib (TargetMol #T3338), or tuvusertib (TargetMol #T10406) was added for 3 days.

Techniques: Organoids

Journal: Scientific Reports

Article Title: Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells

doi: 10.1038/s41598-026-38550-3

Figure Lengend Snippet: Radiation induced G2 arrest. Exponentially growing cells were treated with increasing concentrations of tuvusertib and after 2 h irradiated as indicated. At 12 h after irradiation the cells were fixed, and the cell cycle distribution assessed by DAPI staining and flow cytometry. Results are based on 3 individual experiments per cell line. Graphs display mean and standard deviation.

Article Snippet: IAP inhibition was performed using 1 μM xevinapant (MedChemExpress) and ATR inhibition was performed using 30 nM tuvusertib (MedChemExpress) unless indicated otherwise.

Techniques: Irradiation, Staining, Flow Cytometry, Standard Deviation

Journal: Scientific Reports

Article Title: Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells

doi: 10.1038/s41598-026-38550-3

Figure Lengend Snippet: Cell proliferation. Cells were seeded and after 3 h treated with substances as indicated. Five days later the respective numbers of cells were assessed. ( A ) Treatment with xevinapant and tuvusertib, ( B ) treatment with xevinapant and olaparib, ( C ) treatment with xevinapant and cisplatin and (D) treatment with tuvusertib and olaparib. Graphs ( A ) and ( B ) share identical DMSO and xevinapant values because the results were generated in combined experiments. Data are presented as normalized to the mean of the respective DMSO controls. Significant differences to DMSO-treated samples are indicated with *, ** and *** indicating p < 0.05, p < 0.01 and p < 0.001, respectively (paired, two-tailed Student’s t-test). Dotted lines indicate the number of cells seeded (normalized). Results are based on at least 3 individual experiments per cell line. Graphs display mean and standard deviation.

Article Snippet: IAP inhibition was performed using 1 μM xevinapant (MedChemExpress) and ATR inhibition was performed using 30 nM tuvusertib (MedChemExpress) unless indicated otherwise.

Techniques: Generated, Two Tailed Test, Standard Deviation

Journal: Scientific Reports

Article Title: Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells

doi: 10.1038/s41598-026-38550-3

Figure Lengend Snippet: Colony formation. Cells were seeded in defined low numbers and after 3 h treated with substances as indicated for 26 h, except for xevinapant with an incubation time of 1 week. Cultures were incubated until formation of colonies. ( A ) Treatment with xevinapant and tuvusertib, ( B ) treatment with xevinapant and olaparib, ( C ) treatment with xevinapant and cisplatin and ( D ) treatment with tuvusertib and olaparib. Graphs ( A ) and ( B ) share identical DMSO and xevinapant values because the results were generated in combined experiments. Significant differences to the respective solvent controls are indicated with *, ** and *** indicating p < 0.05, p < 0.01 and p < 0.001, respectively (paired, two-tailed Student’s t-test). Results are based on at least 4 individual experiments per cell line. Graphs display mean and standard deviation.

Article Snippet: IAP inhibition was performed using 1 μM xevinapant (MedChemExpress) and ATR inhibition was performed using 30 nM tuvusertib (MedChemExpress) unless indicated otherwise.

Techniques: Incubation, Generated, Solvent, Two Tailed Test, Standard Deviation

Journal: Scientific Reports

Article Title: Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells

doi: 10.1038/s41598-026-38550-3

Figure Lengend Snippet: Radiosensitization. Cells were seeded in defined low numbers and after 3 h treated with substances as indicated for 26 h, except for xevinapant with an incubation time of 1 week. Cultures were incubated until formation of colonies. Graphs represent the normalized dose response curves from the same experiments as shown in Fig. . ( A ) Treatment with xevinapant and tuvusertib, ( B ) treatment with xevinapant and olaparib, ( C ) treatment with xevinapant and cisplatin and ( D ) treatment with tuvusertib and olaparib. Graphs ( A ) and ( B ) share identical DMSO and xevinapant values because the results were generated in combined experiments. Significant differences to the respective solvent controls are indicated with *, ** and *** indicating p < 0.05, p < 0.01 and p < 0.001, respectively (paired, two-tailed Student’s t-test). Results are based on at least 4 individual experiments per cell line. Dose–response curves display mean and standard deviation.

Article Snippet: IAP inhibition was performed using 1 μM xevinapant (MedChemExpress) and ATR inhibition was performed using 30 nM tuvusertib (MedChemExpress) unless indicated otherwise.

Techniques: Incubation, Generated, Solvent, Two Tailed Test, Standard Deviation

Journal: Cancers

Article Title: Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11

doi: 10.3390/cancers13184601

Figure Lengend Snippet: Pharmacological targets and drugs inducing replication stress.

Article Snippet: Additional drugs are in early development comprising M4344 and M1774 (EMD-Serono Merck, Darmstadt, Germany), ART0380 (Artios Pharma, New York, NY, USA) and RP-3500 (Repare Therapeutics, Quebec, QC, Canada) [ ].

Techniques: Biomarker Discovery, Synthesized, Blocking Assay, Inhibition